Get started
Author

Ivette Orosa-Vázquez

Observed names: Ivette Orosa, Ivette Orosa Vázquez, Ivette Orosa-Vazquez, Orosa Vázquez, Ivette, Orosa-Vázquez, Ivette
ORCID: 0000-0003-3818-3271
Observed ORCID: 0000-0003-3818-3271
OpenAlex ID: A5083028754
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
2021 · Arturo Chang-Monteagudo, Rolando Ochoa-Azze, et al. · The Lancet Regional Health - Americas · 51
PDF
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 38
PDF
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 33
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 31
PDF
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
2021 · Darielys Santana-Mederos, Rocmira Perez-Nicado, et al. · RSC Chemical Biology · 30
PDF
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
2022 · Rolando Ochoa-Azze, Arturo Chang-Monteagudo, et al. · The Lancet Respiratory Medicine · 29
PDF
A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies
2022 · Franciscary Pi-Estopiñan, María Teresa Pérez, et al. · Vaccine · 10
PDF
Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein
2024 · Beatriz Pérez-Massón, Yazmina Quintana-Pérez, et al. · Scientific Reports · 7
PDF
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · medRxiv · 5
PDF
Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients
2024 · Ivette Orosa Vázquez, Marianniz Díaz, et al. · Journal of Immunology Research · 1
PDF
Primer brote de COVID-19 en Cuba. Factores de riesgo de morbimortalidad y respuesta específica de anticuerpos en convalecientes
2024 · Zuñiga Rosales, Yaima, Marcheco-Teruel, Beatriz, et al. · Anales de la Academia de Ciencias de Cuba
PDF
Evaluación preclínica y clínica de SOBERANA® 01. Candidato vacunal contra la COVID-19
2023 · Climent Ruiz, Yanet, Santana Mederos, Darielys, et al. · Anales de la Academia de Ciencias de Cuba
PDF
SOBERANA®Plus: refuerzo seguro y eficaz de la inmunidad natural preexistente contra SARS-CoV-2
2023 · Verez Bencomo, Vicente, Ochoa Azze, Rolando, et al. · Anales de la Academia de Ciencias de Cuba
PDF
Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial
2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal
Análisis exploratorio de seguridad e inmunogenicidad de vacuna HER-1/VSSP en pacientes asintomáticos con cáncer de próstata metastásico
2021 · Iraida Caballero Aguirrechu, Belinda Sánchez Pérez, et al.
Works count: 15
Citation count: 235
H-index: 7
I10-index: 7
Year
Topic
Type